8-KLeadership ChangesOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 6, 2023)

Filed January 6, 2023For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant change in its Board of Directors structure, effective January 5, 2023. The Board size was expanded to twelve, and Dr. Carolyn R. Bertozzi was elected as a new Class III director, with her term set to expire at the 2025 annual meeting of stockholders. Dr. Bertozzi's appointment brings new expertise to the board, and her compensation as a non-employee director includes an annual cash fee of $55,000 and initial stock options valued at $600,000, with further annual stock awards anticipated. This move signifies the company's commitment to strengthening its governance and leveraging external expertise. Furthermore, the company disclosed leadership transitions within its Board. Michael W. Bonney transitioned from his role as Executive Chair to serve as a regular director. Concurrently, Amy W. Schulman has been appointed as the new Chair of the Board. These changes, detailed in a press release furnished with the filing, indicate a strategic shift in board leadership and governance responsibilities, aiming to enhance operational oversight and strategic direction.

Key Highlights

  • 1Alnylam Pharmaceuticals expanded its Board of Directors from eleven to twelve members.
  • 2Dr. Carolyn R. Bertozzi was elected as a new Class III director, serving until the 2025 annual meeting.
  • 3Dr. Bertozzi's compensation as a non-employee director includes a $55,000 annual cash fee and a $600,000 stock option grant.
  • 4Dr. Bertozzi's initial stock option grant vests ratably over three years, with an exercise price of $225.68 per share.
  • 5Michael W. Bonney transitioned from Executive Chair to a director role.
  • 6Amy W. Schulman has been appointed as the new Chair of the Board.
  • 7The company furnished a press release detailing these board changes and appointments.

Frequently Asked Questions

Dr. Carolyn R. Bertozzi is a newly elected Class III director. While the filing doesn't detail her specific background, her election to a newly created vacancy and the expansion of the board suggest the company sought to bring in new expertise and strengthen its governance.

As a non-employee director, Dr. Bertozzi will receive an annual cash fee of $55,000. Upon her election, she was granted stock options to purchase 4,268 shares with a grant date fair value of $600,000, vesting over three years. She is also eligible for future annual stock option awards, currently valued at $400,000 per year.

Effective January 5, 2023, Michael W. Bonney transitioned from Executive Chair to a director. Amy W. Schulman, previously the Lead Independent Director, has been appointed as the new Chair of the Board.

The initial stock option grant of 4,268 shares vests ratably in three annual installments starting on the one-year anniversary of the grant date (January 5, 2023). Future annual stock option awards will vest in full on the one-year anniversary of their respective grant dates.